Literature DB >> 28242674

In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in China.

Yu Pang1, Huiwen Zheng2, Yaoju Tan3, Yuanyuan Song2, Yanlin Zhao4.   

Abstract

The main goal of our study was to evaluate the in vitro bedaquiline susceptibility of six prevalent species of pathogenic nontuberculous mycobacteria (NTM) in China. In addition, we investigated the potential molecular mechanisms contributing to bedaquiline resistance in the different NTM species. Among slowly growing mycobacteria (SGM), bedaquiline exhibited the highest activity against Mycobacterium avium; the MIC50 and MIC90 values were 0.03 and 16 mg/liter, respectively. Among rapidly growing mycobacteria (RGM), Mycobacterium abscessus subsp. abscessus (M. abscessus) and Mycobacterium abscessus subsp. massiliense (M. massiliense) seemed more susceptible to bedaquiline than Mycobacterium fortuitum, with MIC50 and MIC90 values of 0.13 and >16 mg/liter, respectively, for both species. On the basis of bimodal distributions of bedaquiline MICs, we proposed the following epidemiological cutoff (ECOFF) values: 1.0 mg/liter for SGM and 2.0 mg/liter for RGM. Among M. avium, Mycobacterium intracellulare, Mycobacterium kansasii, M. abscessus, M. massiliense, and M. fortuitum isolates, 14 (29.8%), 41 (27.2%), 33 (39.3%), 44 (20.2%), 42 (25.8%), and 7 (31.8%), respectively, were resistant to bedaquiline. No significant differences in the proportions of bedaquiline resistance among these species were observed (P > 0.05). Genetic mutations were observed in 74 isolates (10.8%), with all nucleotide substitutions being synonymous. In conclusion, our data demonstrate that bedaquiline shows moderate in vitro activity against NTM species. Using the proposed ECOFF values, we could distinguish between bedaquiline-resistant and -susceptible strains with the broth dilution method. In addition, no nonsynonymous mutations in the atpE gene that conferred bedaquiline resistance in all six NTM species were identified.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  ECOFF; bedaquiline; nontuberculous mycobacteria

Mesh:

Substances:

Year:  2017        PMID: 28242674      PMCID: PMC5404590          DOI: 10.1128/AAC.02627-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria.

Authors:  Stephanie Petrella; Emmanuelle Cambau; Aurelie Chauffour; Koen Andries; Vincent Jarlier; Wladimir Sougakoff
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 2.  The treatment of rapidly growing mycobacterial infections.

Authors:  Shannon H Kasperbauer; Mary Ann De Groote
Journal:  Clin Chest Med       Date:  2014-11-05       Impact factor: 2.878

3.  Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system.

Authors:  Gabriela Torrea; Nele Coeck; Christel Desmaretz; Tim Van De Parre; Tijs Van Poucke; Nacer Lounis; Bouke C de Jong; Leen Rigouts
Journal:  J Antimicrob Chemother       Date:  2015-05-14       Impact factor: 5.790

4.  In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex.

Authors:  Barbara A Brown-Elliott; Julie V Philley; David E Griffith; Foram Thakkar; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

5.  In vivo evaluation of antibiotic activity against Mycobacterium abscessus.

Authors:  Isabelle Lerat; Emmanuelle Cambau; Romain Roth Dit Bettoni; Jean-Louis Gaillard; Vincent Jarlier; Chantal Truffot; Nicolas Veziris
Journal:  J Infect Dis       Date:  2013-11-18       Impact factor: 5.226

6.  Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China.

Authors:  Zhijian Zhang; Yu Pang; Yufeng Wang; Chad Cohen; Yanlin Zhao; Changting Liu
Journal:  Int J Antimicrob Agents       Date:  2015-03-01       Impact factor: 5.283

7.  Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system.

Authors:  Anna Milano; Maria Rosalia Pasca; Roberta Provvedi; Anna Paola Lucarelli; Giulia Manina; Ana Luisa de Jesus Lopes Ribeiro; Riccardo Manganelli; Giovanna Riccardi
Journal:  Tuberculosis (Edinb)       Date:  2008-10-11       Impact factor: 3.131

8.  The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study.

Authors:  Wouter Hoefsloot; Jakko van Ingen; Claire Andrejak; Kristian Angeby; Rosine Bauriaud; Pascale Bemer; Natalie Beylis; Martin J Boeree; Juana Cacho; Violet Chihota; Erica Chimara; Gavin Churchyard; Raquel Cias; Rosa Daza; Charles L Daley; P N Richard Dekhuijzen; Diego Domingo; Francis Drobniewski; Jaime Esteban; Maryse Fauville-Dufaux; Dorte Bek Folkvardsen; Noel Gibbons; Enrique Gómez-Mampaso; Rosa Gonzalez; Harald Hoffmann; Po-Ren Hsueh; Alexander Indra; Tomasz Jagielski; Frances Jamieson; Mateja Jankovic; Eefje Jong; Joseph Keane; Wo-Jung Koh; Berit Lange; Sylvia Leao; Rita Macedo; Turid Mannsåker; Theodore K Marras; Jeannette Maugein; Heather J Milburn; Tamas Mlinkó; Nora Morcillo; Kozo Morimoto; Dimitrios Papaventsis; Elia Palenque; Mar Paez-Peña; Claudio Piersimoni; Monika Polanová; Nalin Rastogi; Elvira Richter; Maria Jesus Ruiz-Serrano; Anabela Silva; M Pedro da Silva; Hulya Simsek; Dick van Soolingen; Nora Szabó; Rachel Thomson; Teresa Tórtola Fernandez; Enrico Tortoli; Sarah E Totten; Greg Tyrrell; Tuula Vasankari; Miguel Villar; Renata Walkiewicz; Kevin L Winthrop; Dirk Wagner
Journal:  Eur Respir J       Date:  2013-04-18       Impact factor: 16.671

Review 9.  Diagnosis of nontuberculous mycobacterial infections.

Authors:  Jakko van Ingen
Journal:  Semin Respir Crit Care Med       Date:  2013-03-04       Impact factor: 3.119

10.  A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis.

Authors:  Gregory J Fox; Dick Menzies
Journal:  Infect Dis Ther       Date:  2013-08-02
View more
  31 in total

1.  In Vitro Activities of Bedaquiline and Delamanid against Nontuberculous Mycobacteria Isolated in Beijing, China.

Authors:  Xia Yu; XiaoPan Gao; Chenghai Li; Jingjing Luo; Shuan Wen; Tingting Zhang; Yifeng Ma; Lingling Dong; Fen Wang; Hairong Huang
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium abscessus Complex.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

3.  Comparison of In Vitro Activity and MIC Distributions between the Novel Oxazolidinone Delpazolid and Linezolid against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis in China.

Authors:  Zhaojing Zong; Wei Jing; Jin Shi; Shu'an Wen; Tingting Zhang; Fengmin Huo; Yuanyuan Shang; Qian Liang; Hairong Huang; Yu Pang
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

4.  Bedaquiline Inhibits the ATP Synthase in Mycobacterium abscessus and Is Effective in Infected Zebrafish.

Authors:  Christian Dupont; Albertus Viljoen; Sangeeta Thomas; Françoise Roquet-Banères; Jean-Louis Herrmann; Kevin Pethe; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

5.  In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.

Authors:  Dae Hun Kim; Byung Woo Jhun; Seong Mi Moon; Su-Young Kim; Kyeongman Jeon; O Jung Kwon; Hee Jae Huh; Nam Yong Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 6.  Skin and Soft Tissue Infections Due to Nontuberculous Mycobacteria.

Authors:  Elizabeth Ann Misch; Christopher Saddler; James Muse Davis
Journal:  Curr Infect Dis Rep       Date:  2018-03-19       Impact factor: 3.725

7.  Efficacy of Bedaquiline, Alone or in Combination with Imipenem, against Mycobacterium abscessus in C3HeB/FeJ Mice.

Authors:  Vincent Le Moigne; Clément Raynaud; Flavie Moreau; Christian Dupont; Jérôme Nigou; Olivier Neyrolles; Laurent Kremer; Jean-Louis Herrmann
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

8.  In Vitro Activity of PBTZ169 against Multiple Mycobacterium Species.

Authors:  Jin Shi; Jie Lu; Shu'an Wen; Zhaojing Zong; Fengmin Huo; Jingjing Luo; Qian Liang; Yunxu Li; Hairong Huang; Yu Pang
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

9.  Mycobacterial Membrane Proteins QcrB and AtpE: Roles in Energetics, Antibiotic Targets, and Associated Mechanisms of Resistance.

Authors:  Luke Bown; Santosh K Srivastava; Brandon M Piercey; Clarissa K McIsaac; Kapil Tahlan
Journal:  J Membr Biol       Date:  2017-11-02       Impact factor: 1.843

10.  In Vitro Activity of Clofazimine against Nontuberculous Mycobacteria Isolated in Beijing, China.

Authors:  Jingjing Luo; Xia Yu; Guanglu Jiang; Yuhong Fu; Fengmin Huo; Yifeng Ma; Fen Wang; Yuanyuan Shang; Qian Liang; Yi Xue; Hairong Huang
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.